GI ASCO Orlando 2010
- This topic has 4 replies, 4 voices, and was last updated 14 years, 4 months ago by
.
-
Posts
-
Katja…..thank you. As Stacie has mentioned: Our work is a gift of love to those touched by this disease.
Also, I wanted to mention the upcoming webinar, March 23rd. featuring the active cholangiocarcinoma clinical trial entitled, “Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct.” Principal Investigator Dr. Edgar Ben-Josef of the University of Michigan will lead the discussion of this clinical trial. A question and answer session will follow Dr. Ben-Josef’s remarks.
This particular clinical trial is similar to the above mentioned trial.
Love to all,
MarionMarion,
I find this very interesting. Although as you say a small group it does give some hope particularly for my dad’s trial.
Thank you for posting it. I can’t seem to access ASCO’s abstracts at the moment. I agree with Gavin and Lainy, your work is absolutely tireless.
KateHi Marion and so sorry about the rain! We have had STORMS since Tuesday with winds up to 35MPH. They came in from California. Supposed to quiet down tomorrow.
Your report sound excellent. Goes to show that something is coming up all the time and makes us feel we are far from alone any more. I too want to thank you for all you do for all of us. For those who have not had the pleasure of meeting you, you are one phenomenal woman!Hi Marion,
Many thanks for this and indeed for everything that you do. Your efforts are much appreciatted by us all. The Chi-square test, I remember that from my uni days when I had to do stats and calculus as some of the modules that I had to do. Not good!
I hope the rain clears up for you in Florida and that you enjoy the rest of the conference.
Best wishes as always,
Gavin
Hello All,
I have escaped the rain and storm in California and am enjoying the rain and storm in Florida although; here it is tropical and appears periodically, only.
The GI ASCO consists of a consortium of the American Gastroenterological Institute, (AGA) the American Society of Clinical Oncology, (ASCO) the American Society for Radiation Oncology, (ASTRO) and the Society of Surgical Oncology. This three-day multidisciplinary symposium focuses on gastrointestinal cancers only.
As most of you know already the Gem/Cis combination has been established as the very first standard of treatment for Cholangiocacinoma as it has clearly demonstrated increased life expectancy. This does not mean though, that all other medications are not also still used. Various reasons may exclude certain patients, such as intolerance, inefficiency, and etc. from the Gem/Cis combination.
This board has ongoing discussions regarding adjunctive therapies for resectable cholangiocarcinoma and I thought this abstract might be of interest to you. Do remember though, this is a small study group and it is a retrospective study.
This study was conducted at Princess Margaret Hospital, Toronto, Canada; University of Toronto, Canada. Investigators: A.M Horgan, H.H. Al Husainy, S. Cleary, L.A. Dawson, C. Ma, J.J. Knox.
Background: There is no consensus on optimal adjunctive treatment strategies for respectable Bile Duct Cancer. Current approaches involve (neo)adjuvant chemotherapy, chemo radiation therapy or radiotherapy without supporting evidence. The aim of this study is to review treatments utilized in our institutions and explore outcomes in relation to each.
Methods: We reviewed all records of BDC patients treated at PMH between 1990 and 2007. We identified those treated with curative resection and (neo)adjuvant therapy. Age, performance status, tumor characteristics (histology, tumor location, margins and lymph node status) and treatment details (surgical procedure, CT, RT and toxicity data) were collected. A comparison of survival outcomes between RT, CRT and CT arms was undertaken and the difference
Between proportions calculated by the Chi-square test.
Results: Thirty-eight patients treated with curative resection and (neo) adjuvant therapy with a median age of 56 years (32
- The forum ‘Announcements’ is closed to new topics and replies.